Back

RAC study - urinary albumin-to- creatinine ratio: a risk factor in Cardio-Oncology?

20 June 2026 (08:30 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Stratification, Prevention and Monitoring CCO Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Andres Jose Daniele

Institute of Oncology Angel H. Roffo, Buenos Aires (Argentina)

40 More presentations in this session

Presentation thumbnail
Absence of detectable cardiotoxicity with L-Annamycin despite high cumulative anthracycline exposure
Mr S. Waymack (Blacksburg, US)
Abstract Slides
Presentation thumbnail
Pre-existing cardiovascular disease at cancer diagnosis: national trends and future projections in england
Mr A. Alshahrani (Riyadh, SA)
Abstract Slides
Presentation thumbnail
Causal analysis of radiation dose to the base of the heart and overall survival in lung cancer using targeted maximum likelihood estimation
Mr B. Jiang (Manchester, GB)
Abstract Slides
Presentation thumbnail
High prevalence of embolic complications among cancer patients with non-bacterial thrombotic endocarditis
Doctor M. Merhi (Berlin, DE)
Abstract Slides
Presentation thumbnail
Cardio-oncology in breast cancer patients: descriptive data from a north african cohort
Doctor M. Elelmi (Tunis, TN) Doctor E. Bennour Ep Rabah (Tunis, TN)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Angina of the kidney and the heart: the presence and prognostic impact of albuminuria in light of modern guideline-directed medical therapy in heart failure with reduced ejection fraction
31 August 2025
thumbnail
Congress Presentation
Cardiovascular risk factors in oncology: A cross-sectional analysis of patients undergoing chemo-radiotherapy at a tertiary care center
21 June 2025
thumbnail
Congress Presentation
The CRP/albumin ratio: a novel predictor of in-stent restenosis after carotid artery stenting
28 August 2020
thumbnail
Congress Presentation
Systemic H-FABP, hs-cTnT, hs-CRP and Monocyte-to-Lymphocyte ratio were significantly reduced by sacubitril/valsartan in doxorubicin-treated preclinical models through NLRP3-mTOR-AKT pathways
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources